簇集素:重型蛛网膜下腔出血中的新型脑脊液生物标志物——一项先导研究
该先导研究纳入27例重型蛛网膜下腔出血(SAH)患者,于出血后0-3、5-7、10-14天采集47份脑脊液样本,并与25例年龄性别匹配的健康对照比较。SAH后脑脊液簇集素浓度即刻降低,5-7天时预后良好组显著高于预后不良组,且与3个月格拉斯哥预后评分相关。
要点
- 健康对照脑脊液簇集素均值1908.5 ng/mL±36.0,显著高于SAH患者组(P<0.001)。
- SAH后5-7天预后良好组脑脊液簇集素显著高于预后不良组(P=0.017)。
- SAH后5-7天脑脊液簇集素与3个月格拉斯哥预后评分相关(相关系数=0.633)。
核心结论
- SAH与脑脊液簇集素浓度即刻降低相关,某一时间点的簇集素水平可较好预测预后,可能作为生物标志物。
研究设计与样本
- 先导研究,纳入27例重型SAH患者,采集47份脑脊液样本(SAH后0-3、5-7、10-14天),对照为25例因小手术行脊髓麻醉的年龄性别匹配健康受试者。
- 采用酶联免疫吸附试验检测簇集素浓度,并与炎症标志物、影像学表现及治疗结局进行比较。
主要发现
- 健康对照脑脊液簇集素均值1908.5 ng/mL±36.0,显著高于患者组(P<0.001)。
- 患者组脑脊液簇集素均值:SAH后0-3天741.1 ng/mL±759.2,5-7天601.6 ng/mL±507.2,10-14天639.2 ng/mL±446.8。
- SAH后0-3天和10-14天,簇集素水平未能区分预后良好(格拉斯哥预后评分4-5)与预后不良(格拉斯哥预后评分1-3)(P=0.238和P=0.225)。
- SAH后5-7天,预后良好组脑脊液簇集素水平显著高于预后不良组(P=0.017)。
- SAH后5-7天脑脊液簇集素与3个月格拉斯哥预后评分显著相关(相关系数=0.633),与世界神经外科医师联盟量表相关性最佳(相关系数=-0.741)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation following subarachnoid hemorrhage (SAH) involves numerous mediators with biomarker properties. Preliminary studies indicated that clusterin, a multifunctional chaperon protein, was a potential biomarker in SAH. We aimed to clarify the status of clusterin in SAH. METHODS: From 27 patients with severe SAH, 47 cerebrospinal fluid (CSF) samples were collected 0-3, 5-7, and 10-14 days after SAH. Control CSF was collected from 25 age- and sex-matched healthy control subjects undergoing spinal anesthesia for minor surgery. Clusterin concentrations were assayed using enzyme-linked immunosorbent assay and compared with inflammatory markers, imaging findings, and treatment outcome. RESULTS: In healthy control subjects, mean CSF clusterin level (1908.5 ng/mL ± 36.0) was significantly higher than in the patient group (P < 0.001). In the patient group, mean clusterin level was 741.1 ng/mL ± 759.2 0-3 days, 601.6 ng/mL ± 507.2 5-7 days, and 639.2 ng/mL ± 446.8 10-14 days after SAH. Clusterin level failed to differentiate between good (Glasgow Outcome Scale 4-5) and poor (Glasgow Outcome Scale 1-3) outcomes 0-3 days and 10-14 days after SAH (P = 0.238 and P = 0.225), but significantly higher levels of CSF clusterin were found 5-7 days after SAH in patients with good outcome (P = 0.017). There was a significant correlation between CSF clusterin level 5-7 days after SAH and Glasgow Outcome Scale at 3 months (correlation coefficient = 0.633). The best correlation was found for World Federation of Neurological Societies scale (correlation coefficient = -0.741). CONCLUSIONS: SAH is associated with immediate decrease in CSF clusterin concentrations. Clusterin level at one point was a good predictor of outcome, and it may serve as a biomarker.
引用
- Wąsik N, Sokół B, Hołysz M, et al. Clusterin, a New Cerebrospinal Fluid Biomarker in Severe Subarachnoid Hemorrhage: A Pilot Study. World Neurosurg. 2017. PMID: 28803177. doi:10.1016/j.wneu.2017.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。